Karyopharm Therapeutics, Inc. (KPTI)
9.67
0.00 (0.00%)
USD |
NASDAQ |
Feb 20, 16:00
9.675
0.00 (0.00%)
Pre-Market: 20:00
Karyopharm Therapeutics SG&A Expense (Quarterly) : 22.77M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 325.37M |
| Baxter International, Inc. | 761.00M |
| Bruker Corp. | 247.20M |
| Catalyst Pharmaceuticals, Inc. | 42.21M |
| Agios Pharmaceuticals, Inc. | 51.61M |